ERBB2 and breast cancer: In MDA-MB-231 breast cancer cells, oncogenes such as PIK3CA, CCND1, HER2, and WNT1 were significantly downregulated, particularly in the FEO-CSNP treatment group, indicating the suppression of proliferative and metastatic signaling pathways.